UY30244A1 - Un proceso para preparar derivados de tetrahidroquinolina - Google Patents

Un proceso para preparar derivados de tetrahidroquinolina

Info

Publication number
UY30244A1
UY30244A1 UY30244A UY30244A UY30244A1 UY 30244 A1 UY30244 A1 UY 30244A1 UY 30244 A UY30244 A UY 30244A UY 30244 A UY30244 A UY 30244A UY 30244 A1 UY30244 A1 UY 30244A1
Authority
UY
Uruguay
Prior art keywords
tetrahydroquinoline
preparing
diseases
tetrahydroquinoline derivatives
prepare derivatives
Prior art date
Application number
UY30244A
Other languages
English (en)
Inventor
Norimitsu Hayashi
Yoshinori Nakamura
Hitoshi Kubota
Takeshi Hamada
Yoshikazu Mori
Akira Sakuragi
Masaki Okamoto
Takanori Higashijima
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of UY30244A1 publication Critical patent/UY30244A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4

Abstract

La presente invencion provee un proceso pra preparar derivados optimamente activos de tetrahidroquinolina que se pueden usar durante el tratamiento y/o la prevencion de enfermedades tales como enfermedades arterioscleroticas, dislipidemia y similares, y un proceso para preparar sus intermediarios sintéticos. Específicamente, se prepara (2R, 4S)-2-etil-6-trifluormetil-1,2,3,4-tetrahidroquinolin-4-ilamina o una de sus sales con menos etapas, sin usar resolucion optica, y los derivados de tetrahidroquinolina opticamente activos se obtienen a partir del compuesto amina.
UY30244A 2006-03-30 2007-03-26 Un proceso para preparar derivados de tetrahidroquinolina UY30244A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006092783 2006-03-30
JP2006322845 2006-11-30

Publications (1)

Publication Number Publication Date
UY30244A1 true UY30244A1 (es) 2007-11-30

Family

ID=38123770

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30244A UY30244A1 (es) 2006-03-30 2007-03-26 Un proceso para preparar derivados de tetrahidroquinolina

Country Status (10)

Country Link
US (1) US8084611B2 (es)
EP (2) EP2154132A1 (es)
JP (1) JP5275971B2 (es)
AR (1) AR060174A1 (es)
AT (1) ATE533747T1 (es)
ES (1) ES2374315T3 (es)
PE (1) PE20071150A1 (es)
TW (1) TW200808731A (es)
UY (1) UY30244A1 (es)
WO (1) WO2007116922A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090982A1 (es) 2007-11-05 2009-08-13 Novartis Ag Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
EP2229356B1 (en) * 2007-12-03 2011-10-12 Novartis AG 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
CN102020608B (zh) * 2010-09-17 2012-09-05 清华大学 喹啉化合物的制备方法
CA2958040C (en) * 2014-08-12 2022-09-13 Dezima Pharma B.V. Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
WO2017023165A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
MX2020004071A (es) 2017-10-02 2020-07-28 Arixa Pharmaceuticals Inc Derivados de aztreonam y usos de los mismos.
EP3590927A1 (en) 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
CA3114618C (en) 2018-10-01 2023-09-05 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
CA3133071A1 (en) 2019-03-12 2020-09-17 Arixa Pharmaceuticals, Inc. Crystalline form of an avibactam derivative
US11565999B2 (en) 2019-04-25 2023-01-31 Arixa Pharmaceuticals, Inc. Methods of synthesizing aztreonam derivatives
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
JP2023553343A (ja) 2020-11-25 2023-12-21 アカゲラ・メディスンズ，インコーポレイテッド 核酸を送達するための脂質ナノ粒子および関連する使用方法
JP2024513155A (ja) 2021-03-05 2024-03-22 ニューアムステルダム・ファルマ・ベー・フェー 認知症の治療のためのオビセトラピブ
KR20240040767A (ko) 2021-07-26 2024-03-28 뉴암스테르담 파마 비.브이. His 저감반응자의 치료
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
CN114516865B (zh) * 2022-03-09 2023-06-23 成都师范学院 一类D-π-A型有机共轭分子及其制备方法和应用
WO2024009144A1 (en) 2022-07-05 2024-01-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
WO2024042061A1 (en) 2022-08-22 2024-02-29 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI82094C (fi) 1989-02-16 1997-09-09 Valmet Corp Anvaendning av en legering av ett metallpulver och en karbid eller nitrid innefattande belaeggningskomposition foer en i en pappersmaskin anvaendbar yankeecylinder
IL93610A0 (en) 1989-03-08 1990-12-23 Merck Sharp & Dohme Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them
NO903525L (no) 1989-08-11 1991-02-12 Ici Plc Nitrogenforbindelser.
JPH03161360A (ja) 1989-11-21 1991-07-11 Tdk Corp サーマルヘッド
JPH03216566A (ja) 1990-01-22 1991-09-24 Mitsubishi Electric Corp Ｃｃｄリニアイメージセンサのテスト装置
GB9010394D0 (en) 1990-05-09 1990-06-27 Ici Plc Heterocyclic compounds
IE914573A1 (en) 1991-01-17 1992-07-29 Ici Plc Boron compounds
JPH05213884A (ja) 1991-06-14 1993-08-24 Upjohn Co:The 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5929281A (en) 1996-04-19 1999-07-27 Tosoh Corporation Process for producing heterocyclic aromatic amine or arylamine
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
EP1167521A1 (en) 2000-06-30 2002-01-02 Aventis Animal Nutrition S.A. Coated enzyme-containing catalyst
WO2002008869A2 (en) 2000-07-25 2002-01-31 Digeo, Inc. Allowance account for interactive television system
JP2002053557A (ja) * 2000-08-14 2002-02-19 Japan Tobacco Inc アポリポ蛋白ａ−ｉ産生促進薬
WO2002016329A1 (fr) * 2000-08-18 2002-02-28 Ajinomoto Co., Inc. Nouveaux derives de phenylalanine
SE0101161D0 (sv) * 2001-03-30 2001-03-30 Astrazeneca Ab New compounds
BR0209238A (pt) 2001-04-30 2004-06-15 Pfizer Prod Inc Compostos úteis como intermediários
EP1318139A3 (en) 2001-12-07 2003-07-30 Solvias AG Processes for the preparation of 3-aminocarboxylic acids and their esters
US6903233B2 (en) 2002-03-11 2005-06-07 Takasago International Corporation Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester
DK1533292T3 (da) 2002-08-30 2007-06-04 Japan Tobacco Inc Dibenzylaminforbindelse og medicinsk anvendelse deraf
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2004238322A (ja) 2003-02-05 2004-08-26 Sumika Fine Chemicals Co Ltd （ｒ）−３−アミノペンタンニトリルメタンスルホン酸塩の製造方法
WO2004072041A1 (en) 2003-02-12 2004-08-26 Care X S.A. Tetrahydroquinolines as agonists of liver- x receptors
JP4644658B2 (ja) 2003-02-18 2011-03-02 高砂香料工業株式会社 光学活性テトラヒドロキノリン類の製造方法
EA200501376A1 (ru) 2003-03-28 2006-04-28 Пфайзер Продактс Инк. Производные 1,2,4-замещённых 1,2,3,4-тетрагидро- и 1,2-дигидрохинолинов и 1,2,3,4-тетрагидрохиноксалина в качестве ингибиторов сетр для лечения атеросклероза и тучности
JP2004339205A (ja) 2003-04-24 2004-12-02 Ajinomoto Co Inc 光学活性Ｎ−アリール−β−アミノ酸化合物の製造方法
US7145030B2 (en) 2003-04-24 2006-12-05 Ajinomoto Co., Inc. Production method for optically active N-aryl-β-amino acid compounds
WO2005028419A2 (en) 2003-09-18 2005-03-31 Takasago International Corporation Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives
WO2005087714A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
PL1732933T3 (pl) 2004-03-26 2008-12-31 Lilly Co Eli Związki do leczenia dyslipidemii
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2005336083A (ja) 2004-05-26 2005-12-08 Sumitomo Chemical Co Ltd 芳香族アミノ化合物の製造方法
WO2006012093A1 (en) 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia

Also Published As

Publication number Publication date
JP5275971B2 (ja) 2013-08-28
JP2009532345A (ja) 2009-09-10
EP2007728B1 (en) 2011-11-16
WO2007116922A1 (en) 2007-10-18
AR060174A1 (es) 2008-05-28
ES2374315T3 (es) 2012-02-15
TW200808731A (en) 2008-02-16
US8084611B2 (en) 2011-12-27
PE20071150A1 (es) 2007-12-03
EP2154132A1 (en) 2010-02-17
EP2007728A1 (en) 2008-12-31
ATE533747T1 (de) 2011-12-15
US20090292125A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
UY30244A1 (es) Un proceso para preparar derivados de tetrahidroquinolina
CR20150625A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
UY33815A (es) Composiciones y métodos para modular el fxr
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CU24091B1 (es) Derivados de 2-(piridin-4-il)piridina o sales de los mismos como moduladores de proteína quinasa cdk9 y composiciones farmacéuticas que los comprenden
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
UY34888A (es) Inhibidores del virus de la hepatitis c
BR112012007828A2 (pt) compostos, processo para preparar os compostos, e, composição farmacêutica.
CR20170392A (es) Compuestos bicíclicos de sulfonamida cetona
CL2010001468A1 (es) Compuestos derivados de adamantildiamida, moduladores alostericos del receptor 5 glutamato metabotropico (mglur5); composicion farmaceutica que los comprende; y uso para tratar una enfermedad o trastorno del snc tal como depresion, ansiedad, esquizofrenia y enfermedad de parkinson.
SV2009003346A (es) Compuestos triciclicos, composiciones y procedimientos.
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
ECSP089019A (es) Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa
MA37886A1 (fr) Nouvelles pyridinones bicycliques
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
GT201400242A (es) "nuevos compuestos de pirazol"
CL2011000865A1 (es) Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras.
DOP2011000053A (es) Agentes antifungicos
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
EA200900985A1 (ru) Способ получения оптически чистого омепразола

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170602